Revenue surged nearly 16 times to $13.2 million in the 1HFY2022 from $830,000 due to the income from the out-licensing of Wafermine to Seelos Therapeutics in November 2021.
iX Biopharma has reported net profit of $3.7 million for the 1HFY2022 ended December, reversing from its loss of $2.8 million in the same period the year before.
1HFY2022 earnings per share (EPS) stood at 0.49 cents from the loss per share of 0.41 cents in the 1HFY2020.
